Chronic pancreatitis is the most common cause of PEI – 80 to 90% of these patients will have some degree of PEI.1 In patients with chronic pancreatitis and PEI, digestive lipase output has been shown to be about 2.5 IU/min – less than 0.2% of normal (3,000 IU/min).1 In order to avoid steatorrhoea, lipase secretion of greater than 5 to 10% of normal is needed, precipitating the need for effective Pancreatic Enzyme Replacement Therapy (PERT).1
Creon® has been shown to improve symptoms associated with PEI
Creon improved the following symptoms at 1 week and at 52 weeks versus baseline:2,3*
Adapted from Thorat V et al. Aliment Pharmacol Ther 2012; Ramesh H. et al. Pancreatology 2013.
There were also significant improvements at 52 weeks in coefficients of fat absorption (CFA) and nitrogen absorption (CNA) versus baseline:3
**Values are estimations taken from graphs within the published paper as exact values unpublished.
Creon has been shown to significantly improve patients’ nutritional status3*
Several nutritional parameters significantly improved from baseline in patients with chronic pancreatitis.
Adapted from Ramesh H. et al. Pancreatology 2013
Dose of 80,000 lipase units/meal; 40,000 lipase units/snack; 6-9 capsules per day.
Creon has been shown to improve quality of life as measured by the SF-36® Health Survey questionnaire3
At 52 weeks, patient quality of life had improved from baseline with statistically significant changes in:
- bodily pain
- general health
- emotional well-being
- mental health
- mental component summary.
***p=0.001 vs. baseline; **p<0.01 v. baseline; *p<0.05 vs. baseline.
Adapted from Ramesh H et al. Pancreatology 2013
OLE: Open-label extension – 52 weeks.
- Keller J et al. Gut 2005; 54(Suppl6): 1-28.
- Thorat V. Aliment Pharmacol Ther. 2012; 36(5): 426-36.
- Ramesh H. Pancreatology 2013; 13: 133-9.
- Imrie CW et al. Aliment Pharm Ther. 2010; 32(Suppl1):1-25